Skip to content

Clinical effect of controlled ovarian stimulation using progesterone and hMG in PCOS patients undergoing IVF/ICSI- a double blinded, randomed controlled test

Clinical effect of controlled ovarian stimulation using progesterone and hMG in PCOS patients undergoing IVF/ICSI- a double blinded, randomed controlled test

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-16009580
Enrollment
Unknown
Registered
2016-10-24
Start date
2016-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovarian syndrome

Interventions

MPA group:controlled stimulation using hMG and MPA
antagonist group:controlled stimulation using hMG and antagonist

Sponsors

Department of Assisted Reproduction, Shanghai Ninth People’s hospital affiliated to JiaoTong University School of Medicine,
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. PCOS patient who oligo- and/or anovulation, clinical or biochemical signs of hyperandrogenism and polycystic ovaries; 2. thesecriteria are inaccordancewiththe revised 2003 Rotterdam criteria for PCOS; 3. Aged 18 to 39 years, no endometriotic cyst present, as assessed by trans-vaginal ultrasound examination.

Exclusion criteria

Exclusion criteria: 1. clinically significant systemic disease such as renal failure; 2. endometriosis grade 3 or higher; 3. documented ovarian failure including basal FSH above 10 IU/l; 4. received hormonal treatments in the previous three months; 5. any contraindications to ovarian stimulation treatment; 6. Patients with known previous poor ovarian response.

Design outcomes

Primary

MeasureTime frame
effective number of embryos;

Countries

China

Contacts

Public ContactYun Wang

Department of Assisted Reproduction, Shanghai ninth people’s hospital affiliated to JiaoTong University School of Medicine

sammy20080228@aliyun.com+86 021-23271699-5538

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026